SUPPLEMENTARY DATA

Supplementary Table 1. Lipids at baseline/12 weeks (mmol/L)

	Liraglutide 1.2 mg	Placebo	P-value
Total cholesterol	4.6±0.2 / 4.3±0.1	4.4±0.1 / 4.4±0.1	0.66
HDL cholesterol	1.7±0.1 / 1.5±0.1	1.5±0.1 / 1.4±0.1	0.29
LDL cholesterol	2.5±0.2 / 2.3±0.1	2.4±0.1 / 2.4±0.1	0.62
VLDL cholesterol	0.45±0.04 / 0.43±0.04	0.53±0.08 / 0.53±0.05	0.09
Triacylglycerol (TAG)	1.02±0.08 / 0.95±0.09	1.18±0.18 / 1.20±0.11	0.09

Data are presented as mean±SE; P-value: comparison between group at week 12

SUPPLEMENTARY DATA

Supplementary Table 2. Adverse events (AE) and serious adverse events (SAE)

	Liraglutide 1.2	Placebo
Number of patients	20	20
GI AE, patients (n)		
Nausea	13	9
Dyspepsia	7	2
Abdominal pain	2	1
Diarrhea	0	4
Constipation	1	0
Vomiting	2	3
Ructus	1	4
Other GI discomfort	2	0
Total	28	23
Other AE, patients (n)		
Pneumonia	1	0
Rhinitis	1	4
Headache	1	2
Exacerbation of psoriasis	0	1
Gastroenteritis	0	1
Depression	0	1
Restlessness	0	1
Mild cramps in calf and feet	0	1
Cystitis	2	0
Influenza-like symptoms	2	1
Retinal hemorrhage	0	1
Loss of appetite	9	0
Experience of food loathing	1	0
Dizziness	2	0
Tiredness	5	0
Coughing	1	0
Local skin- reaction	1	0
Total	26	13
SAE, patients (n)		
Humerus fracture	1	0
Onset of sarcoidosis	1	0
Hip fracture	1	0
Severe hypoglycemia	1	0
Major depression	0	1
Total	4	1

GI indicates gastrointestinal; AE, adverse events; local skin-reaction, reaction at the site of IMP injection; IMP, investigational medicinal product; SAE, serious adverse events; Major depression, depression with psychotic features requiring hospitalization.